Kentucky Network for Innovation & Commercialization (“KYNETIC”)
Kentucky Network for Innovation & Commercialization (“KYNETIC”)
批准号:
10022341
负责人:
Paula J. Bates
金额:
$97.74万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-23 至 2023-08-31
关键词:
AddressAreaBackBiomedical ResearchBusinessesClinicCollaborationsComplement 3aDevelopmentDevicesDiagnostic testsEconomic DevelopmentEconomicsEcosystemEducationEntrepreneurshipEvaluation ResearchFederal GovernmentFund RaisingFundingGoalsGrantHealthHealth BenefitHumanIndividualIndustryInstitutionKentuckyKnowledgeLaboratoriesLeadershipLicensingMedical DeviceMentorsMissionModelingPaperPharmacologic SubstancePrincipal InvestigatorPrivate SectorPrivatizationProcessPublishingResearchResourcesRiskServicesSiteSourceState GovernmentStructureSystemTechnologyTechnology TransferTextTranslational ResearchTranslationsUnderrepresented GroupsUnited StatesUnited States National Institutes of HealthUniversitiesWorkbiomedical resourcecollegecommercializationcommunity collegeexperiencehealth disparityimprovedindustry partnerinnovationinterestmembernovel therapeuticsprogramspublic-private partnershiprole modelskill acquisitionsynergismtechnical collegetool
中文摘要
摘要
学术研究所产生的知识是与卫生有关的创新的主要来源。转化
将创新发现转化为改善人类健康的商业化产品是一个艰难的过程。然而,在这方面,
所有利益相关者(大学、资助机构、制药和医疗器械行业、联邦和州
政府和公众)在确定可扩展的方法以加速
将学术创新转化为生物医学产品。肯塔基州创新网络的目标是
研究评估和商业化中心(Research Evaluation and Commercialization Hub,REACH)
在整个肯塔基州联邦可访问的商业化资源网络,以加速
将学术创新转化为生物医学产品。为实现这一目标,将实现以下目标:
进行:1)建立KYNETIC的组织和协作结构; 2)寻找,资助和管理产品
定义/发展项目; 3)提供指导、技能发展、体验式教育和网络
与行业专家,企业家和投资者的机会;以及4)制定和实施计划,
向自我维持的实体过渡。KYNETIC将借鉴开发区域IDEA的经验教训
技术转移加速器(在英国)和当前的REACH中心(在UL)。KYNETIC将由大学领导
肯塔基州(英国),与路易斯维尔大学(UL)和英联邦商业化
中心(C3),一个私人501(c)3非营利性商业化组织。此外,KYNETIC将包括所有
肯塔基州的公立区域大学和社区技术学院系统(KCTCS)。KYNETIC的
使命是通过提供资金、指导、教育和
相关专业知识网络。肯塔基州已全额承诺为KYNETIC提供所需的配套资金
联邦经济发展(CED)和州立R1大学。Kynetic将由一位
领导团队由2名学术创新者,2名技术转移专业人员(来自英国和UL)和
2名伙伴实体代表(C3和CED)。包括领导团队的指导委员会
和来自每个参与机构的代表,外部审查委员会和NIH将审查和
评估KYNETIC项目,并使用创新的“快速终止”管理策略,每年资助多达13个项目。
我们的服务将提供给尽可能多的人。包括创新者在内的各种榜样,
将寻找代表性不足群体的企业家。拟议中的剑桥范围的REACH计划将
利用我们的集体资源、生态系统和丰富经验,以最佳方式应用和扩展
创新者教育和指导的实践。KYNETIC的整体影响将是前所未有的
合作和协同作用的机会,准备充分的创新者,全州范围内的亲创业文化
提供降低风险的技术,以造福健康,克服国家的健康差距。
英文摘要
ABSTRACT
Knowledge generated by academic research is a major source of health-related innovations. Transforming
innovative discoveries into commercialized products that improve human health is a difficult process. However,
all stakeholders (universities, funding bodies, pharmaceutical and medical device industries, federal and state
governments and the public) have a vested interest in identifying scalable approaches that accelerate the
translation of academic innovations into biomedical products. The goal of the Kentucky Network for Innovation
and Commercialization (KYNETIC) is to build a Research Evaluation and Commercialization Hub (REACH)
network of commercialization resources accessible across the entire Commonwealth of Kentucky to accelerate
translation of academic innovations into biomedical products. To reach this goal, the following aims will be
conducted: 1) establish KYNETIC’s organizational and collaborative structure; 2) Find, fund and manage product
definition/development projects; 3) Provide mentoring, skills development, experiential education and networking
opportunities with industry experts, entrepreneurs and investors; and 4) Devise and implement a plan to
transition to a self-sustaining entity. KYNETIC will build on lessons learned from developing a regional IDeA
technology transfer accelerator (at UK) and a current REACH hub (at UL). KYNETIC will be led by the University
of Kentucky (UK), in partnership with the University of Louisville (UL) and the Commonwealth Commercialization
Center (C3), a private 501(c)3 non-profit commercialization organization. Also, KYNETIC will include all of
Kentucky’s public regional universities and community and technical college system (KCTCS). KYNETIC’s
mission is to nurture innovations and academic innovators by providing funding, mentoring, education and a
network of relevant expertise. Required matching funds for KYNETIC have been committed in full by Kentucky
Commonwealth Economic Development (CED) and the state R1 universities. KYNETIC will be directed by a
leadership team consisting of 2 academic innovators, 2 technology transfer professionals (from UK and UL) and
2 representatives from partnering entities (C3 and CED). A steering committee including the leadership team
and representatives from each participating institution, an External Review Board and the NIH will review and
evaluate KYNETIC projects and fund up to 13 projects/yr using an innovative “quick kill” management strategy.
Our services will be available to as many individuals as possible. Diverse role models including innovators and
entrepreneurs from underrepresented groups will be sought. The proposed Kentucky-wide REACH program will
leverage our collective wealth of resources, ecosystems and extensive experience to apply and expand best
practices for innovator education and mentoring. The overall impact of KYNETIC will be unprecedented
opportunities for collaboration and synergy, well-prepared innovators, a statewide pro-entrepreneurial culture
and delivery of de-risked technologies to benefit health and overcome the state’s health disparities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Kentucky Network for Innovation & Commercialization (“KYNETIC”)
-
批准号:9897157
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2019
-
负责人:Paula J. Bates
-
依托单位:
Kentucky Network for Innovation & Commercialization (“KYNETIC”)
-
批准号:10240675
-
项目类别:
-
资助金额:$96.79万
-
财政年份:2019
-
负责人:Paula J. Bates
-
依托单位:
The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship
-
批准号:9038438
-
项目类别:
-
资助金额:$99.92万
-
财政年份:2015
-
负责人:Paula J. Bates
-
依托单位:
Tumor-Targeting Oligonucleotides
-
批准号:7269380
-
项目类别:
-
资助金额:$25.51万
-
财政年份:2006
-
负责人:Paula J. Bates
-
依托单位:
Tumor-Targeting Oligonucleotides
-
批准号:7474633
-
项目类别:
-
资助金额:$25.51万
-
财政年份:2006
-
负责人:Paula J. Bates
-
依托单位:
Tumor-Targeting Oligonucleotides
-
批准号:7906006
-
项目类别:
-
资助金额:$25.51万
-
财政年份:2006
-
负责人:Paula J. Bates
-
依托单位:
Tumor-Targeting Oligonucleotides
-
批准号:7662572
-
项目类别:
-
资助金额:$25.51万
-
财政年份:2006
-
负责人:Paula J. Bates
-
依托单位:
Tumor-Targeting Oligonucleotides
-
批准号:7132949
-
项目类别:
-
资助金额:$26.27万
-
财政年份:2006
-
负责人:Paula J. Bates
-
依托单位:
A Role for Nucleolin in Malignant Transformation?
-
批准号:6826563
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2004
-
负责人:Paula J. Bates
-
依托单位:
A Role for Nucleolin in Malignant Transformation?
-
批准号:6933846
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2004
-
负责人:Paula J. Bates
-
依托单位:
Nucleolin--A Novel Target for Cancer Drug Discovery
-
批准号:6515048
-
项目类别:
-
资助金额:$14.4万
-
财政年份:2001
-
负责人:Paula J. Bates
-
依托单位:
Nucleolin--A Novel Target for Cancer Drug Discovery
-
批准号:6333892
-
项目类别:
-
资助金额:$14.4万
-
财政年份:2001
-
负责人:Paula J. Bates
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: